INHIBACE

This brand name is authorized in Austria, Canada, Poland, South Africa, Turkey.

Active ingredients

The drug INHIBACE contains one active pharmaceutical ingredient (API):

1	Cilazapril UNII 19KW7PI29F - CILAZAPRIL
	Cilazapril is a specific, long-acting angiotensin-converting enzyme (ACE) inhibitor which suppresses the renin-angiotensin-aldosterone system and thereby the conversion of the inactive angiotensin I to angiotensin II, which is a potent vasoconstrictor.
	Read more about Cilazapril

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
INHIBACE Tablet	MPI, CA: SPM	Health Products and Food Branch (CA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09AA08	Cilazapril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	01911473, 01911481
PL	Rejestru Produktów Leczniczych	100030624, 100030630, 100042521, 100057391, 100246904, 100259284, 100265304, 100283578, 100294056, 100326098, 100334293, 100334301, 100342200, 100343620, 100344191, 100360617, 100360623, 100398057, 100435338
TR	İlaç ve Tıbbi Cihaz Kurumu	8699511099003, 8699511099010, 8699511099027
ZA	Health Products Regulatory Authority	Y/7.1.3/66